share_log

ACHV: First Quarter 2022 Results

ACHV: First Quarter 2022 Results

ACHV:2022年第一季度业绩
Benzinga Real-time News ·  2022/05/13 10:56
By John Vandermosten, CFA
约翰·范德莫斯滕,CFA
NASDAQ:ACHV
纳斯达克:非典病毒
READ THE FULL ACHV RESEARCH REPORT
阅读ACHV研究报告全文
Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported first quarter 2022 results in a press release and held a conference call after market close on May 12, 2022. The company concurrently filed its Form 10-Q with the SEC. Highlights for 2022 include impressive topline results from the ORCA-21 trial, launch of the ORCA-3 trial, participation in various investor and scientific conferences and expansion of its manufacturing and quality and operations team and a board member addition.
成就生命科学公司(纳斯达克:ACHV)在新闻稿中公布了2022年第一季度业绩,并于2022年5月12日收盘后召开了电话会议。该公司同时向美国证券交易委员会提交了10-Q表格。2022年的亮点包括ORCA-2令人印象深刻的背线结果1此外,我们还参与了ORCA-3试验,参加了各种投资者和科学会议,扩大了制造、质量和运营团队,并增加了一名董事会成员。
Achievements for the first quarter ended March 31st and to-date include:
截至3月31日的第一季度和到目前为止的成就包括:
➢ ORCA-2 last subject, last follow up...
➢ORCA-...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发